Journal of Antimicrobial Chemotherapy (2002) 49, 763-767
© 2002 The British Society for Antimicrobial Chemotherapy
Effect of gemifloxacin on viability of Chlamydia pneumoniae (Chlamydophila pneumoniae) in an in vitro continuous infection model
Department of Pediatrics, State University of New York Downstate Medical Center, 450 Clarkson Avenue, Box 49, Brooklyn, NY 11203-2098, USA
Received 4 July 2001; returned 27 November 2001; revised 8 February 2002; accepted 18 February 2002.
Persistent infection with Chlamydia pneumoniae (Chlamydophila pneumoniae) has been implicated in the development of atherosclerosis, asthma and other chronic diseases. However, data on treatment of C. pneumoniae infections are limited. Microbiological failure of antimicrobial therapy has been described, even after prolonged courses of treatment with azithromycin, doxycycline and erythromycin. Gemifloxacin is an enhanced-affinity fluoroquinolone with excellent activity against most common respiratory pathogens, including C. pneumoniae. The effect of prolonged treatment with gemifloxacin, compared with azithromycin, on viability of C. pneumoniae was investigated in a continuous infection model. Gemifloxacin at final con-centrations of 0.25 and 2.5 mg/L reduced the viability of C. pneumoniae by 5 log10, which was similar to the effect of azithromycin. However, both antimicrobials failed to completely eliminate C. pneumoniae from continuously infected cells, even after 30 days of treatment. Both antibiotics decreased levels of interleukin-6 and interleukin-8 in this model, but this effect appeared to be secondary to the antichlamydial activity, as the cytokine levels correlated with the concentrations of microorganisms.
* Corresponding author. Tel: +1-718-245-4075; Fax: +1-718-245-2118; E-mail: mhammerschlag{at}pol.net
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. Caronzolo, V. Lucini, M. Pannacci, S. Grosso, N. Kieffer, L. Bello, A. Bikfalvi, and F. Scaglione Effect of PEX, a Noncatalytic Metalloproteinase Fragment with Integrin-Binding Activity, on Experimental Chlamydophila pneumoniae Infection. Antimicrob. Agents Chemother., October 1, 2006; 50(10): 3277 - 3282. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Siewert, J. Rupp, M. Klinger, W. Solbach, and J. Gieffers Growth Cycle-Dependent Pharmacodynamics of Antichlamydial Drugs Antimicrob. Agents Chemother., May 1, 2005; 49(5): 1852 - 1856. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Hermann, K. Gueinzius, A. Oehme, S. von Aulock, E. Straube, and T. Hartung Comparison of Quantitative and Semiquantitative Enzyme-Linked Immunosorbent Assays for Immunoglobulin G against Chlamydophila pneumoniae to a Microimmunofluorescence Test for Use with Patients with Respiratory Tract Infections J. Clin. Microbiol., June 1, 2004; 42(6): 2476 - 2479. [Abstract] [Full Text] [PDF]
|
|